Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1992-12-01
1996-12-10
Naff, David M.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241411, 424 9463, 424 9464, 53038825, 53038226, A61K 39395, A61K 3848
Patent
active
055828620
ABSTRACT:
The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to .alpha.2-antiplasmin crosslinked to fibrin (.alpha.2AP-Fx) which does not inhibit plasma .alpha.2-antiplasmin (.alpha.2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward .alpha.2-antiplasmin crosslinked to fibrin which does not inhibit plasma .alpha.2AP together with a thrombolytic agent.
REFERENCES:
patent: 4147765 (1979-04-01), Stephan et al.
patent: 4198335 (1980-04-01), Collen
patent: 4245040 (1981-01-01), Pilgeram
patent: 4273873 (1981-06-01), Sugitachi et al.
patent: 4346029 (1982-08-01), Collen
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4455290 (1984-06-01), Olexa et al.
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4474893 (1984-10-01), Reading
patent: 4545988 (1985-10-01), Nakayama et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4722903 (1988-02-01), Kudryk et al.
patent: 4758524 (1988-07-01), Bundesen et al.
patent: 4833085 (1989-05-01), Schaumann et al.
patent: 4916070 (1990-04-01), Matsueda et al.
patent: 4927916 (1990-05-01), Matsueda et al.
patent: 5116613 (1992-05-01), Haber et al.
patent: 5372812 (1994-12-01), Reed et al.
patent: 5487892 (1996-01-01), Gargan
Bates et al, Circulation, 84(6):2463-2469, Dec. 1991.
Waldmann, T., "Monoclonal Antibodies in Diagnosis and Therapy", Science, vol. 252, pp. 1657-1662, Jun. 1991
Harris et al., "Therapeutic Antibodies-the Coming of Age", T. BTECH, vol. 11 pp. 42-44, 1993.
Agnelli et al., "The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits", Thrombosis and Haemostasis 63(2):204-207 (1990).
Agnelli et al., "A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits", Circulation 72(1):178-182 (1985).
Agnelli et al., "Sustained thrombolysis with DNA", Blood 66(2):399-401 (Aug. 1985).
Angles-Cano, E. R., "Tissue plasminogen activator determination with a fibrin-supported film", Chem. Abstracts 104:307-308, Abstract No. 144639d (1986).
Aoki, N. et al., "Fibrin-associated plasminogen activation in .alpha..sub.2 -plasmin inhibitor deficiency", Blood 62(5):1118-1122 (Nov. 1983).
Bode et al., "Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator", Circulation 81(6):1974-1980 (Jun. 1990).
Bode et al., "Antibody-directed urokinase: a specific fibrinolytic agent", Science 229:765-767 (Aug. 23, 1985).
Bode et al., "Thrombolysis by a fibrin-specific antibody Fab'urokinase conjugate", J. Mol. Cell Cardiol. 19:335-341 (1987).
Bode et al., "Antibody-directed fibrinolysis", J. Biol. Chem. 264(2):944-948 (Jan. 15, 1989).
Boulianne et al., "Production of functional chimaeric mouse/human antibody", Nature 312:643-646 (Dec. 13, 1984).
Branscomb et al., "Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator", Thrombosis and Haemostasis 64(2):260-266 (1990).
Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G.sub.1 fragments", Science 229:81-83 (Jul. 5, 1985).
Carrasquillo et al., "Radioimmunodetection of human melanoma with monoclonal antibodies and Fab fragments", Radioimaging and Radioimmunotherapy, Burchiol and Rhodes, Eds., Elsevier Science Publishing Co., Inc., pp. 357-368 (1983).
Charpie et al., "A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase", Biochemistry 29(27):6374-6378 (1990).
Collen et al., "Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis", J. Clin. Invest. 71:368-376 (Feb. 1983).
Collen et al., "Thrombolytic and pharmacokinetic properties of chimeric tissue-type ad urokinase-type plasminogen activators", Circulation 84(3):1216-1234 (Sep. 1991).
Collen et al., "Synergism of thrombolytic agents in vivo", Circulation 74(4):838-842 (Oct. 1986).
DeWood et al., "Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction", New England J. of Medicine 303(16):897-902 (Oct. 16, 1980).
Dorai et al., "The effect of dihydrofolate reductase-mediated gene amplification on the expression of transfected immunoglobulin genes", J. Immunol. 139(12):4232-4241 (Dec. 15, 1987).
Duberstein, R., "Scientists develop new technique for producing bispecific monoclonals", Genetic Engineering News 6:22 (1986).
Emeis, J. J. and Verheijen, J. H., "Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor-and kringle one-domains", Arzneim.-Forsch./Drug Res. 42(3):358-362 (1992).
Fisher et al., "Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5' flanking region", J. Biol. Chem. 260(20):11223-11230 (Sep. 15, 1985).
Gardell et al., "Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits", Circulation 84(1):244-253 (Jul. 1991).
Gold et al., "Acute coronary reocclusion after thrombolysis with recombinatnt human tissue-tyype plasminogen activator: prevention by a maintenance infusion", Circulation 73(2):347-352 (Feb. 1986).
Haber, E. et al., "Antibody targeting as a thrombolytic strategy", Annals of the New York Academy of Sciences, pp. 365-381 (Dec. 1992).
Hattey, E. et al., "Monoclonal antibodies against plasminogen and alpha-2-antiplasmin: binding to native and modified antigens", Thromb. Res. 45:485-495 (1987).
Hessel et al., "Primary structure of human fibrinogen and fibrin", Eur. J. Biochem. 98:521-534 (1979).
Houranieh et al., "Monoclonal antibodies to human cross-linked fibrin", Fed. Proc. 44:1846, Abstract No. 8381 (1985).
Hui et al., "Immunodetection of human frbin using monoclonal antibody-64C5 in an extracorporeal chicken model", Thrombosis and Haemostasis 54(2):524-527 (1985).
Hui et al., "Monoclonal antibodies of predetermined specificity for fibrin: a rational approach to monoclonal antibody production", Hybridoma 5(3):215-222 (1986).
Hui et al., "Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen", Science 222:1129-1132 (Dec. 9, 1983).
Ito, R. K., "Fibrinolysis studies: fibrinogen-specific antibody as carriers for fibrinolytic agents", Fed Proc. 44:1846, Abstract No. 8382 (1985).
Kabnick, K. S. and Housman, D. E., "Determinants that contribute to cytoplasmic stability of human c-fos and .beta.-globin mRNAs are located at several sites in each mRNA", Mol. Cell. Biol. 8(8):3244-3250 (Aug. 1988).
Kato et al., "A specific immunoassay system for hybrid type antigens", Chem. Abstracts 94:325, Abstract No. 61048j (1981).
Kimura, S. et al., "Acceleration of fibrinolysis by the N-terminal peptide of .alpha..sub.2 -plasmin inhibitor", Blood 66(1):157-160 (Jul. 1985).
Kudryk et al., "A monoclonal antibody with ability to distinguish between NH.sub.2 -terminal fragments derived from fibrinogen and fibrin", Molecular Immunology 20(11):1191-1200 (1983).
Kudryk et al., "Specificity of a monoclonal antibody for the NH.sub.2 -terminal region of fibrin", Molec. Immunol. 21(1):89-94 (1984).
Kumada, T. and Abiko, Y., "Physiological role of .alpha.-.sub.2 -plasmin inhibitor in rats", Thrombosis Research 36:153-163 (1984).
Laffel, G. L. and Braunwald, E., "A new strategy for the treatment of acute myocardial infarction (first of two parts)", New England J. of Medicine 311(11):710-717 (Sep. 13, 1984).
Laffel, G. L. and Braunwald, E., "A new strategy for the treatment of acute myocardial infarction (second of two parts)", New England J. of Medicine 311(12):770-776 (Sep. 20, 1984).
Lanzavecchia, A. Scheidegger, D., "The use of hybrid hybridomas to targ
Haber Edgar
Matsueda Gary R.
Reed Guy L.
General Hospital Corporation
Larson Kristin
Naff David M.
LandOfFree
Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-422398